Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Josep Maria Miquel"'
Publikováno v:
ESMO Open, Vol 4, Iss Suppl 2 (2019)
Externí odkaz:
https://doaj.org/article/b61c9c2b346b4b89a96d5b30dfa8e53b
Autor:
Cristina Saura, Carolina Ortiz, Enrique Javier Arenas, Judit Matito, Anna Suñol-Camas, Octavi Cordoba, Alex Martinez-Sabadell, Itziar Garcia-Ruiz, Ignacio Miranda, Clara Morales-Comas, Estela Carrasco Lopez, Cristina Viaplana, Vicente Peg, Paolo Nuciforo, Neus Bayo, Josep Maria Miquel, Marina Gomez-Rey, Guillermo Villacampa, Silvia Arevalo, Javier Carmona, Martín Espinosa-Bravo, Judith Balmaña, Rodrigo Dienstmann, Joaquin Arribas, Josep Tabernero, miriam sanso, Ana Vivancos
Publikováno v:
Cancer Research. 83:P1-05
The potential of cell-free tumor DNA (ctDNA) for early tumor detection in asymptomatic patients is yet to be established. In the case of pregnancy associated breast cancer (BC), early detection is of special interest, since it is an entity of special
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86f0c9840cb91806db446ced933e33b6
https://doi.org/10.1158/1538-7445.sabcs22-p1-05-14
https://doi.org/10.1158/1538-7445.sabcs22-p1-05-14
Autor:
Paula Romero Lozano, Maria Vila-Casadesús, Judit Matito, Carmen García-Duran, Deborah Grazia Lo Giacco, Marina Gómez-Rey, Juan Francisco Grau, Lorena Fariñas-Madrid, Eva Hernández-Illán, Agatha Martin, Cecília García, Ester Castillo, Josep Maria Miquel Aymar, Josep Tabernero, Ana Oaknin, Ana Vivancos
Publikováno v:
Journal of Clinical Oncology. 40:5547-5547
5547 Background: Copy number alterations (CNA) arise as a result of somatic changes to chromosome structure, resulting in gain or loss of genomic regions. A likely source of copy number variation is an incorrect repair of DNA damage that causes chrom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b56970369eca495faf69d686bc8e5b3
https://doi.org/10.1200/jco.2022.40.16_suppl.5547
https://doi.org/10.1200/jco.2022.40.16_suppl.5547
Autor:
Carles Fabregat-Franco, Judit Matito, Agatha Martin, Helena Verdaguer, Florian Castet, Josep Maria Miquel Aymar, Gloria Castillo, Alexandre Sierra, Ana Vivancos, Teresa Macarulla
Publikováno v:
Journal of Clinical Oncology. 40:e16302-e16302
e16302 Background: Approximately 80% of pancreatic ductal adenocarcinoma (PDAC) patients present with advanced disease at diagnosis, with a 5-year survival rate of less than 5%. According to molecular profiling, mutations in KRAS have been described
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::442f93739fb8ec906b078c687ef3eb23
https://doi.org/10.1200/jco.2022.40.16_suppl.e16302
https://doi.org/10.1200/jco.2022.40.16_suppl.e16302
Autor:
Gonzalez-Medina, Alberto, Verdaguer, Helena, Vila-Casadesus, Maria, Sierra, Alexandre, Castillo, Gloria, Carles Fabregat Franco, Gomez-Rey, Marina, Aymar, Josep Maria Miquel, Macarulla, Teresa, Vivancos, Ana
Publikováno v:
Web of Science
4085 Background: Actionable genetic alterations can be identified in over 50% of intrahepatic cholangiocarcinoma (iCCA). Since EMA approved Pemigatinib, a selective Fibroblast growth factor receptor 1-3 (FGFR1-3) inhibitor for the treatment of CCA wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ebed9d1a828222719fadaee9504e7b4
https://doi.org/10.1200/jco.2022.40.16_suppl.4085
https://doi.org/10.1200/jco.2022.40.16_suppl.4085
Publikováno v:
Drug Delivery in Oncology. :56-73
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe6e8df83534ae16853f58ae42f2ec55
https://doi.org/10.4155/ebo.13.482
https://doi.org/10.4155/ebo.13.482
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.